Richard Ferrari Biography and Net Worth

Director of Pulmonx

Richard M. Ferrari has served as a member of our Board since February 2007. Mr. Ferrari is the Co-Founder of De Novo Ventures, a healthcare investment firm dedicated to medical devices and bio-technology, and has served as a Managing Director since 2000. Mr. Ferrari also serves as a faculty member of the Stanford Biodesign Emerging Entrepreneurs Forum, as well as a board member for the Stanford Coulter Foundation for Translational Medicine. From October 1995 to May 1999, Mr. Ferrari co-founded and served as the Chief Executive Officer of CardioThoracic Systems, Inc., a surgery medical technology and device company. From January 1990 to June 1995, Mr. Ferrari served as the CEO of Cardiovascular Imaging Systems, a developer of ultrasound imaging. Mr. Ferrari has served on the board of directors of HeartBeam, Inc. since December 2019 and as Executive Chairman since June 2021. Mr. Ferrari holds a B.S. from Ashland University and an M.B.A. from the University of South Florida.

What is Richard Ferrari's net worth?: The estimated net worth of Richard Ferrari is at least $578.90 thousand as of April 16th, 2026. Mr. Ferrari owns 291,636 shares of Pulmonx stock worth more than $578,897 as of September 17th. This net worth approximation does not reflect any other investments that Mr. Ferrari may own. Learn More about Richard Ferrari's net worth.
How do I contact Richard Ferrari?: The corporate mailing address for Mr. Ferrari and other Pulmonx executives is 700 Chesapeake Drive, Redwood City, CA, 94063. Pulmonx can also be reached via phone at 1-650-364-0400 and via email at [email protected]. Learn More on Richard Ferrari's contact information.
Has Richard Ferrari been buying or selling shares of Pulmonx?: Richard Ferrari has not been actively trading shares of Pulmonx over the course of the past ninety days. Most recently, Richard Ferrari sold 8,000 shares of the business's stock in a transaction on Thursday, June 12th. The shares were sold at an average price of $3.16, for a transaction totalling $25,280.00. Following the completion of the sale, the director now directly owns 87,024 shares of the company's stock, valued at $274,995.84. Learn More on Richard Ferrari's trading history.
Who are Pulmonx's active insiders?: Pulmonx's insider roster includes Richard Ferrari (Director), Daniel Florin (Director), Glendon French, III (CEO), Mehul Joshi (CFO), David Lehman (General Counsel), Geoffrey Rose (Insider), and Derrick Sung (CFO). Learn More on Pulmonx's active insiders.
Are insiders buying or selling shares of Pulmonx?: In the last twelve months, insiders at the sold shares 11 times. They sold a total of 202,010 shares worth more than $357,453.20. The most recent insider tranaction occured on September, 1st when CEO Glendon E. French, III sold 41,882 shares worth more than $94,653.32. Insiders at Pulmonx own 7.5% of the company. Learn More about insider trades at Pulmonx.
Information on this page was last updated on 9/1/2026.

Richard Ferrari Insider Trading History at Pulmonx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/12/2025	Sell	8,000	$3.16	$25,280.00	87,024
11/8/2022	Buy	5,438	$5.31	$28,875.78	30,035

Richard Ferrari Buying and Selling Activity at Pulmonx

Pulmonx Company Overview

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Today's Range

Now: $1.99

$1.97

$2.02

50 Day Range

MA: $1.91

$1.17

$2.50

2 Week Range

Now: $1.99

$1.13

$2.89

Volume

185,800 shs

Average Volume

501,065 shs

Market Capitalization

$85.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.34